SCHEMBL10134878

SCHEMBL10134878

CN1CCCCC1CNc1nc2cc(C#N)ccc2c2ccsc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 2/20 0.41
LMNA P02545 1/20 0.39
KAT2B Q92831 1/20 0.38
CSNK2A1 P68400 2/20 0.37
GABRP O00591 2/20 0.36
GABRD O14764 2/20 0.36
GABRA1 P14867 2/20 0.36
GABRB1 P18505 2/20 0.36
GABRG2 P18507 2/20 0.36
GABRB3 P28472 2/20 0.36
GABRA5 P31644 2/20 0.36
GABRA3 P34903 2/20 0.36
GABRA2 P47869 2/20 0.36
GABRB2 P47870 2/20 0.36
GABRA4 P48169 2/20 0.36
GABRE P78334 2/20 0.36
GABRA6 Q16445 2/20 0.36
GABRG1 Q8N1C3 2/20 0.36
GABRG3 Q99928 2/20 0.36
GABRQ Q9UN88 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10136184 0.90 CSNK2A1 (0.44) SLC6A4LMNAKAT2BCSNK2A1GABRP
SCHEMBL10134875 0.86 SLC6A4 (0.40) SLC6A4LMNACSNK2A1GPR6IRAK4
SCHEMBL10134789 0.85 SLC6A4 (0.44) SLC6A4LMNAKAT2BGABRPGABRD
SCHEMBL10134883 0.79 LMNA (0.40) LMNAKAT2BCSNK2A1TERTPDE4A
SCHEMBL10134962 0.79 CSNK2A1 (0.41) SLC6A4LMNACSNK2A1
SCHEMBL10132571 0.75 CSNK2A1 (0.68) CSNK2A1
SCHEMBL10135004 0.73 CSNK2A1 (0.41) CSNK2A1IRAK4
SCHEMBL10134876 0.73 CSNK2A1 (0.54) CSNK2A1
SCHEMBL10134909 0.73 CSNK2A1 (0.67) CSNK2A1TERT
SCHEMBL10132322 0.72 CSNK2A1 (0.42) LMNACSNK2A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120208792-A1 PROTEIN KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2012-08-16 US disclosed
US-20120208792-A1 PROTEIN KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2012-08-16 US disclosed
US-8168651-B2 Protein kinase modulators CYLENE PHARMACEUTICALS, INC. (US) 2012-05-01 US disclosed
US-8168651-B2 Protein kinase modulators CYLENE PHARMACEUTICALS, INC. (US) 2012-05-01 US disclosed
US-20090239859-A1 PROTEIN KINASE MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2009-09-24 US disclosed
US-20090239859-A1 PROTEIN KINASE MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2009-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120208792-A1 PROTEIN KINASE MODULATORS PIM1, PIM2, PIM3 SLC6A4 4414/4885LMNA 3976/4885KAT2B 3167/4885
US-20090239859-A1 PROTEIN KINASE MODULATORS PIM1, PIM2, PIM3 SLC6A4 4414/4885LMNA 3976/4885KAT2B 3167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.